NCT02400814View on ClinicalTrials.gov

MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer

PHASE1TerminatedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

December 3, 2015

Primary Completion Date

September 29, 2021

Study Completion Date

September 29, 2021

Conditions
Recurrent Non-Small Cell Lung CarcinomaStage IV Non-Small Cell Lung Cancer
Interventions
DRUG

Anti-PD-L1 Monoclonal Antibody MPDL3280A

Given IV

RADIATION

Stereotactic Body Radiation Therapy

Undergo SAR

Trial Locations (1)

95817

University of California Davis, Sacramento

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Megan Daly, MD

OTHER